May 06, 2020
Bausch Health And Alfasigma Announce Resolution Of XIFAXAN® Intellectual Property Litigation
Mar 31, 2020
Bausch Health Announces Favorable Topline Results From Study Evaluating Investigative Formulation of Rifaximin SSD IR to Treat Overt Hepatic Encephalopathy
Mar 09, 2020
The irritable bowel syndrome treatment market was valued at $1,071 million in 2018, and is estimated to reach at $2,012 million by 2026, registering a CAGR of 8.2% from 2019 to 2026
Feb 17, 2020
Irritable Bowel Syndrome Treatment Market to Reach $2.01 Bn, Globally, by 2026 at 8.2% CAGR, Says Allied Market Research
Oct 31, 2019
Salix Announces Issuance of an Additional XIFAXAN® Patent
Aug 12, 2019
First Patient Enrolled in Mallinckrodt's Phase 2a Study of Investigational Drug MNK-6106 in Hepatic Cirrhosis and Chronic Hepatic Encephalopathy (HE)
May 14, 2019
Salix Pharmaceuticals Marks 30-Year Anniversary With Largest Showing Of Data At Digestive Disease Week
Apr 25, 2019
Global $385 Mn Traveler's Diarrhea Markets, 2019-2028
Mar 27, 2019
Traveler's Diarrhea Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight
Dec 12, 2018
Bausch Health Enters Into Definitive "Stalking Horse" Agreement To Acquire Substantially All The Assets Of Synergy Pharmaceuticals Inc.
Dec 06, 2018
ZAXINE® (rifaximin) - Now Indicated in Canada for Patients with Irritable Bowel Syndrome with Diarrhea (IBS-D)1,2
Nov 16, 2018
FDA approves new drug to treat travelers' diarrhea
Oct 29, 2018
Salix And Alfasigma Will Initiate Late-Stage Program To Study Rifaximin In Patients With Postoperative Crohn's Disease
Oct 08, 2018
Salix to Present Clinical Data for XIFAXAN® (RIFAXIMIN) and PLENVU® at the American College of Gastroenterology Annual Meeting
Sep 12, 2018
Bausch Health Announces Resolution Of XIFAXAN® Intellectual Property Litigation
Jun 03, 2018
Salix Presents Positive Phase 3 Investigational Study Data For Repeat Rifaximin Treatment In Patients With Diarrhea Predominant Irritable Bowel Syndrome
Jun 03, 2018
Salix Presents Rifaximin Phase 3 Study Results for Irritable Bowel Syndrome with Diarrhea at Digestive Disease Week
May 31, 2018
Salix To Highlight New Clinical Data During Digestive Disease Week